Galapagos NV (NASDAQ:GLPG) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET

Company Participants

Sofie Van Gijsel - Head of IR
Paul Stoffels - Chair of the Board & CEO
Thad Huston - CFO & COO
Jeevan Shetty - Head of Development Oncology
Wulf Bocher - Head Immunology Therapeutic Area

Conference Call Participants

Xian Deng - UBS
Judah Frommer - Morgan Stanley
Alexander Kelly - TD Cowen
Shan Hama - Jefferies
Nevin Varghese - RBC Capital Markets
Jacob Mekhael - KBC Securities
Faisal Khurshid - Leerink Partners
Sebastiaan Van der Schoot - VLK

Operator

Good day, and thank you for standing by. Welcome to the Galapagos Q3 2024 Financial Results Audio Webcast. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Sofie Van Gijsel, please go ahead.

Sofie Van Gijsel

Thank you, and welcome to the audio webcast of Galapagos' Q3 2024 results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos. This recorded webcast is accessible via the Galapagos website homepage and will be available for downloads and replay later today.

We would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments of the pipeline and our company and possible changes in the industry and competitive environment. Because these forward-looking statements involve risks and uncertainties Galapagos' actual results may differ materially from the results expressed or implied in these statements.

Today's speakers are Dr. Paul Stoffels, CEO and Chair; and Thad Huston, CFO and COO. Paul will present the Q3 key takeaways, and Thad will provide a financial update. We will also discuss the anticipated milestones and present concluding remarks.

Please follow the presentation on your screen as we go through the call. We estimate that the prepared remarks will take approximately 20 minutes. We will then open the line for Q&A with Paul and Thad who will also be joined by Dr. Jeevan Shetty, Head of Development Oncology; and Dr. Wulf Bocher, Head of Immunology.

And with that, I'll now turn over to Paul.

Paul Stoffels

Thank you, Sofie, and good afternoon, everyone. I would like to take a moment to share the strong foundation that we are building and how we have set up Galapagos for value creation. Today, we are a pure-play biotech with a renewed R&D strategy to accelerate and bring innovative medicines to patients. We are moving forward faster with the focused, differentiated and expanding R&D pipeline and competitive technology platforms. We're also making important regulatory and operational progress with our decentralized CAR-T network in Europe and the U.S.